What does GeneriX do?

GeneriX is a research organisation in Seraing. Private Limited, started on 13 February 2004, 1 establishment.

What is the address of GeneriX?

The registered office of GeneriX is located at Rue Damry 60, 4100 Seraing.

Is GeneriX still active?

Yes. According to the CBE (30 October 2026) GeneriX is active, legal situation “Normale toestand”, started on 13 February 2004.

Is GeneriX registered on Peppol?

Yes, GeneriX is registered on the Peppol network with ID 0208:0863425803.

What is the enterprise number of GeneriX?

The enterprise number of GeneriX is BE0863425803.

When was GeneriX founded?

GeneriX was founded on 13 February 2004.

Who are the directors of GeneriX?

According to the 2025 annual accounts, the directors of GeneriX are: Christophe GREFFE, Nicolas POELST.

Is GeneriX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 February 2004; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did GeneriX make in 2025?

GeneriX posted a profit after taxes of € 165,675 in financial year 2025.

What is the revenue of GeneriX?

As a small company, GeneriX is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 10,530.

GeneriX (Private Limited) - Seraing - BE0863425803

Dossier GeneriX, printed on 30 October 2026 from databakkes.be/en/0863425803/generix. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

GeneriX from Seraing, company number BE0863425803, closed financial year 2025 with a result of € 165,675 after tax. For that financial year GeneriX recorded a gross margin of € 10,530 and equity of € 961,025. Compared with financial year 2024, the result moved from € -58,252 to € 165,675. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 961,025

▲ € 945,562 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 165,675

▲ still € 58,252 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 198,746

▲ € 197,710 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 168,738.

People and assets in 2025

Wage cost

€ 66,894

▲ 99% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 25,556

▲ 214% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 13,798

▼ 35% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 15,185 Gross margin 2022: € 15,185 First fiscal year in the series	€ 42,472 Gross margin 2023: € 42,472 ▲ 180% vs 2022 (€ 15,185) Favourable step	€ -23,975 Gross margin 2024: € -23,975 ▼ € 66,447 vs 2023 (€ 42,472) Unfavourable step	€ 10,530 Gross margin 2025: € 10,530 ▲ € 34,505 vs 2024 (€ -23,975) Favourable step	▲ € 34,505
Profit after taxes	€ -20,403 Profit after taxes 2022: € -20,403 First fiscal year in the series	€ -26,211 Profit after taxes 2023: € -26,211 ▼ € 5,808 vs 2022 (€ -20,403) Unfavourable step	€ -58,252 Profit after taxes 2024: € -58,252 ▼ € 32,041 vs 2023 (€ -26,211) Unfavourable step	€ 165,675 Profit after taxes 2025: € 165,675 ▲ € 223,927 vs 2024 (€ -58,252) Favourable step	▲ € 223,927
Equity	€ 252,086 Equity 2022: € 252,086 First fiscal year in the series	€ 225,875 Equity 2023: € 225,875 ▼ 10% vs 2022 (€ 252,086) Unfavourable step	€ 15,463 Equity 2024: € 15,463 ▼ 93% vs 2023 (€ 225,875) Unfavourable step	€ 961,025 Equity 2025: € 961,025 ▲ € 945,562 vs 2024 (€ 15,463) Favourable step	▲ € 945,562
Total debts	€ 28,863 Total debts 2022: € 28,863 First fiscal year in the series	€ 61,167 Total debts 2023: € 61,167 ▲ 112% vs 2022 (€ 28,863) Unfavourable step	€ 177,686 Total debts 2024: € 177,686 ▲ 190% vs 2023 (€ 61,167) Unfavourable step	€ 39,354 Total debts 2025: € 39,354 ▼ 78% vs 2024 (€ 177,686) Favourable step	▼ 78%
Cash	€ 37,095 Cash 2022: € 37,095 First fiscal year in the series	€ 55,002 Cash 2023: € 55,002 ▲ 48% vs 2022 (€ 37,095) Favourable step	€ 1,036 Cash 2024: € 1,036 ▼ 98% vs 2023 (€ 55,002) Unfavourable step	€ 198,746 Cash 2025: € 198,746 ▲ € 197,710 vs 2024 (€ 1,036) Favourable step	▲ € 197,710
Retained profit	€ 239,686 Retained profit 2022: € 239,686 First fiscal year in the series	€ 213,475 Retained profit 2023: € 213,475 ▼ 11% vs 2022 (€ 239,686) Unfavourable step	€ 3,063 Retained profit 2024: € 3,063 ▼ 99% vs 2023 (€ 213,475) Unfavourable step	€ 168,738 Retained profit 2025: € 168,738 ▲ € 165,675 vs 2024 (€ 3,063) Favourable step	▲ € 165,675
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 152,160 Dividend 2024: € 152,160 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 152,160) Unchanged	▼ 100%
Balance sheet total	€ 280,949 Balance sheet total 2022: € 280,949 First fiscal year in the series	€ 287,042 Balance sheet total 2023: € 287,042 ▲ 2% vs 2022 (€ 280,949) Unchanged	€ 193,149 Balance sheet total 2024: € 193,149 ▼ 33% vs 2023 (€ 287,042) Unchanged	€ 1,000,379 Balance sheet total 2025: € 1,000,379 ▲ € 807,230 vs 2024 (€ 193,149) Unchanged	▲ € 807,230

Key figures of GeneriX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to GeneriX?

What happened at GeneriX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 165,675. filed late Source: NBB ↗
2025 Nicolas POELST became a director. NBB
2023 Christophe GREFFE became a director. NBB
Feb 13, 2004 New establishment in Liège. KBO
Feb 13, 2004 Start of the company according to the CBE. KBO

In short

From € 20,403 loss in 2022 to € 165,675 profit in 2025.

Best year ever: 2025, with € 165,675 profit.

Paid out € 152,160 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Christophe GREFFE Nicolas POELST

GenomiX

GeneriX

X-RIS

Behind GeneriX are Christophe GREFFE and Nicolas POELST. The same people are also behind GenomiX. Nicolas POELST is also behind X-RIS.

Directors

According to the 2025 annual accounts

Christophe GREFFE

Managing director

Also active at: GenomiX

since 2023

Nicolas POELST

Director

Also active at: GenomiX, X-RIS

since 2025

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Damry 60

4100 Seraing

2.135.551.604

Allée de la Cense-Rouge 9

4031 Liège

Active since 13 February 2004

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Write & Compute

€ 144,836 gross margin · 2025

STRIKE Solutions

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0863.425.803

VAT number

BE 0863.425.803

Registered office

Rue Damry 60, 4100 Seraing

Names & denominations

GeneriX

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

13 February 2004

Peppol

Active · Active since 14 Nov 2025

Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Groothandel in andere consumentenartikelen, neg

Overige groothandel in consumentenartikelen, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗

GeneriX

Financials

What happened to GeneriX?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions